Resources

We are thrilled to share that the The Research Room PPI podcast that Mary and Kate featured in is now live!

Explore invasive fungal infections and gain the skills to diagnose, treat, and prevent them in your healthcare practice.

Recording of the BioDriveAFS Investigators' Day held on the 24th June 2025, 1 hours and 37 minutes

The Haematological Malignancy Research Network provides information about leukaemias, lymphomas, myelomas, and related blood disorders, based on data from the UK.

In the video, two members from the BioDriveAFS Patient Advisory Group, Kate Common and Samantha-Jane Hunt, share their experiences from diagnosis to their involvement in the BioDriveAFS trial.

Presentation on Mycobiome in Acute Leukaemia presented by Thomas Taynton at the Hull and York Medical School (HYMS) Postgraduate Research Conference in July 2023

Outline of mapping of turnaround time, and suggestions to reduce, for invasive fungal infection biomarker tests for BioDriveAFS trial

Recording of the BioDriveAFS Investigators' Day held on the 6th June 2023, 3 hours and 35 minutes

Webinar, 90 minutes duration

Open access on-line e-learning course

Pharmacy professionals are urged to seize the opportunity presented by the BioDrive AFS study, engaging in antimicrobial stewardship research to advance scientific knowledge and showcase leadership in optimizing therapeutic strategies for patients undergoing intensive chemotherapy.

Plain English Summary of (1 → 3)‑β‑d‑Glucan‑guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial

Plain English Summary of Invasive Fungal Disease in Patients with Myeloid Malignancies: A Retrospective Cohort Study of a Diagnostic-Driven Care Pathway Withholding Mould-Active Prophylaxis

Plain English Summary of Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Plain english summary of Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Plain English Summary of Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association

Should serum biomarker monitoring replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy? A PRO/CON debate. Published in the Journal of Antimicrobial Chemotherapy. Authors Thomas Harrison and David Partridge

CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy published in the Journal of of Antimicrobial Chemotherapy. Authors Alex Howard and William Hope (BioDriveAFS Trial Management Group Members)

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia published in the Journal of of Antimicrobial Chemotherapy. Authors Thomas Taynton (Clinical Research Fellow), Gavin Barlow (Co-CI of BioDriveAFS) and David Allsup (Co-CI of BioDriveAFS)

Flow chart to guide decision making for patients in the intrevention arm of the BioDriveAFS Trial

BioDriveAFS Trial Protocol_v2.5 14.01.2025

BioDriveAFS team members Professor David Allsup (Co-Chief Investigator) and Lydia Flett (Trial Manager) sat down with the hosts of the York Trials Unit Podcast, 'The Research Room' to record an episode all about the BioDriveAFS trial.

Recording of the BioDriveAFS Investigators' Day held on the 24th June 2025, 1 hours and 37 minutes

Protocol Paper

Pharmacy professionals are urged to seize the opportunity presented by the BioDrive AFS study, engaging in antimicrobial stewardship research to advance scientific knowledge and showcase leadership in optimizing therapeutic strategies for patients undergoing intensive chemotherapy.

In the video, two members from the BioDriveAFS Patient Advisory Group, Kate Common and Samantha-Jane Hunt, share their experiences from diagnosis to their involvement in the BioDriveAFS trial.

Presentation on Mycobiome in Acute Leukaemia presented by Thomas Taynton at the Hull and York Medical School (HYMS) Postgraduate Research Conference in July 2023

Recording of the BioDriveAFS Investigators' Day held on the 6th June 2023, 3 hours and 35 minutes

Should serum biomarker monitoring replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy? A PRO/CON debate. Published in the Journal of Antimicrobial Chemotherapy. Authors Thomas Harrison and David Partridge

CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy published in the Journal of of Antimicrobial Chemotherapy. Authors Alex Howard and William Hope (BioDriveAFS Trial Management Group Members)

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia published in the Journal of of Antimicrobial Chemotherapy. Authors Thomas Taynton (Clinical Research Fellow), Gavin Barlow (Co-CI of BioDriveAFS) and David Allsup (Co-CI of BioDriveAFS)